EUVIMEDEUVIMED entdecken
Crossref

A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy

Yu Miao, Le Niu, Xinying Lv, Qiang Zhang, Zhisheng Xiao, Zhaoxin Ji, Linfu Chen, Yi Liu, Nanhui Liu, Junjie Zhu, Yang Yang, Qian Chen iD

Advanced Materials · 2024-11 · 36 (44)

DOI: 10.1002/adma.202410715 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 29.08.2024. Verfasst von Yu Miao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, S…. Hauptthemen laut MEDLINE: Immunotherapy, Cancer Vaccines, Mannans, Nanoparticles. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Research Programs of China, National Natural Science Foundation of China, Shanghai Academic Research Leader.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathogen‐mimicking nanoparticles have emerged at the forefront of vaccine delivery technology, offering potent immune activation and excellent biocompatibility. Among these innovative carriers, mannan, a critical component of yeast cell walls, shows promise as an exemplary vaccine carrier. Nevertheless, it faces challenges like unpredictable immunogenicity, rapid elimination, and limited antigen loading due to high water solubility. Herein, mannan with varying carbon chain ratios is innovatively modified, yielding a series of dodecyl chains modified mannan (Mann‐C 12 ). Through meticulous screening, a mannan variant with a 40% grafting ratio is pinpointed as the optimal vaccine carrier. Further RNA sequencing confirms that Mann‐C 12 exhibits desired immunostimulatory characteristics. Coupled with antigen peptides, Mann‐C 12 /OVA 257‐280 nanovaccine initiates the maturation of antigen‐presenting cells by activating the TLR4 and Dectin‐2 pathways, significantly boosting antigen utilization and sparking antigen‐specific immune responses. In vivo, experiments utilizing the B16‐OVA tumor model underscore the exceptional preventive capabilities of Mann‐C 12 /OVA 257‐280 . Notably, when combined with immune checkpoint blockade therapy, it displays a profound synergistic effect, leading to marked inhibition of tumor growth. Thus, the work has yielded a pathogen‐like nanovaccine that is both simple to prepare and highly effective, underscoring the vast potential of mannan‐modified nanovaccines in the realm of cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyCancer VaccinesMannansNanoparticlesAnimalsMiceHumansNeoplasmsCell Line, TumorNanovaccines

Stichwörter der Autor:innen

cancer vaccineimmunotherapymannanminimalist nanovaccinepathogen‐like carrier

Substanzen

Cancer VaccinesMannansNanovaccines

Autor:innen und Institutionen

  • Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, 215123, China.
  • School of Materials Science and Engineering, Tongji University, Shanghai, 201804, China.
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
  • Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.

ORCID-Profile: Qian Chen

Förderung

  • National Research Programs of China
  • National Natural Science Foundation of China
  • Shanghai Academic Research Leader
  • the National Natural Science Foundation of China
  • Program of Shanghai Academic Research Leader

Zitieren

APA

Miao, Y., Niu, L., Lv, X., Zhang, Q., Xiao, Z., Ji, Z., Chen, L., Liu, Y., Liu, N., Zhu, J., Yang, Y., & Chen, Q. (2024). A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy. Advanced Materials, 36(44). https://doi.org/10.1002/adma.202410715

Vancouver

Miao Y, Niu L, Lv X, Zhang Q, Xiao Z, Ji Z, et al. A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy. Advanced Materials. 2024;36(44). doi:10.1002/adma.202410715

BibTeX
@article{Miao2024,
  author = {Miao, Yu and Niu, Le and Lv, Xinying and Zhang, Qiang and Xiao, Zhisheng and Ji, Zhaoxin and Chen, Linfu and Liu, Yi and Liu, Nanhui and Zhu, Junjie and Yang, Yang and Chen, Qian},
  title = {A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy},
  journal = {Advanced Materials},
  year = {2024},
  volume = {36},
  number = {44},
  doi = {10.1002/adma.202410715}
}
Kostenlos starten →